News

March 23, 2020April 15, 2020

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

News

Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — results in a more accurate detection of clinically significant ... Read more

March 19, 2020March 23, 2020

Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

News

Patients with prostate cancer exhibit changes in the levels of some urinary molecules compared with people with benign prostate diseases and healthy individuals, a study found, suggesting that these changes ... Read more

March 18, 2020March 18, 2020

Proscia and UCSF Partnering to Deliver AI Apps to Improve Cancer Diagnosis

News

Proscia and the University of California San Francisco (UCSF) are partnering to use artificial intelligence (AI) to improve the accuracy and speed of cancer diagnoses, starting with prostate cancer. The ... Read more

March 16, 2020March 23, 2020

Veru Advances Prostate Cancer Therapy VERU-111 to Phase 2 Portion of Trial

News

Veru said it initiated the Phase 2 portion of a clinical trial testing the safety and effectiveness of its investigational therapy, VERU-111, in men with metastatic castration-resistant prostate cancer (mCRPC) ... Read more

March 12, 2020March 12, 2020

Adoptive Cell Therapy Can Slow Prostate Cancer Growth, Study in Mice Reports

News

Treating prostate cancer animal models with modified immune cells that were isolated from bone marrow led to a significant reduction in tumor growth, a study in mice reports. These findings ... Read more

March 11, 2020March 23, 2020

Ciforadenant Has Promising Anti-tumor Activity in mCRPC, Early Data Show

News

Treatment with Corvus Pharmaceuticals‘ ciforadenant (CPI-444), alone or in combination with Tecentriq (atezolizumab), is well tolerated and showed promising anti-tumor activity in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, early ... Read more

March 9, 2020March 9, 2020

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

News

Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can identify which men with intermediate or high-risk prostate cancer will benefit from combining androgen ... Read more

March 6, 2020March 12, 2020

3 New miR Scientific Urine Tests Diagnose, Classify Prostate Cancer, Data Shows

News

The bioscience company miR Scientific has presented breakthrough data on three urine-based tests to detect and classify prostate cancer from RNA molecules, called small non-coding RNAs (sncRNAs). The first test, ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare ... Read more

March 4, 2020March 4, 2020

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

News

A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with a relapse after surgery who will benefit most by adding androgen deprivation therapy (ADT) to radiation therapy, ... Read more